Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 156
463
mi
from 43215
Orangeburg, SC
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 156
463
mi
from 43215
Orangeburg, SC
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 158
370
mi
from 43215
Manitowoc, WI
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 158
370
mi
from 43215
Manitowoc, WI
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 114
280
mi
from 43215
Brooklyn, NY
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 114
280
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 160
537
mi
from 43215
New Haven, CT
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 160
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 117
751
mi
from 43215
Daytona Beach, FL
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 117
751
mi
from 43215
Daytona Beach, FL
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 116
771
mi
from 43215
DeBary, FL
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 116
771
mi
from 43215
DeBary, FL
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 103
394
mi
from 43215
Saint Louis, MO
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 103
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0005 2323
849
mi
from 43215
Oklahoma City, OK
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0005 2323
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 129
mi
from 43215
Wyomissing, PA
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 129
mi
from 43215
Wyomissing, PA
Click here to add this to my saved trials
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated:  12/31/1969
As0006 208
mi
from 43215
Camperdown,
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
Status: Enrolling
Updated: 12/31/1969
As0006 208
mi
from 43215
Camperdown,
Click here to add this to my saved trials
Pain Coping Skills Training for African Americans With Osteoarthritis
Pain Coping Skills Training for African Americans With Osteoarthritis
Status: Enrolling
Updated:  12/31/1969
UNC Thurston Arthritis Research Center
353
mi
from 43215
Chapel Hill, NC
Pain Coping Skills Training for African Americans With Osteoarthritis
Pain Coping Skills Training for African Americans With Osteoarthritis
Status: Enrolling
Updated: 12/31/1969
UNC Thurston Arthritis Research Center
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry
Improving Orthopedic Outcomes Through a National TJR Registry
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Health Center; Arthritis and Total Joint Center
604
mi
from 43215
Worcester, MA
FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry
Improving Orthopedic Outcomes Through a National TJR Registry
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Health Center; Arthritis and Total Joint Center
604
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study
A Retrospective Consecutive Series Patient Preference and Clinical Outcomes Study in Bilateral Knee Osteoarthritis Patients With Both Total Knee Arthroplasty and Unicompartment Knee Arthroplasty Prostheses.
Status: Enrolling
Updated:  12/31/1969
Tri County Orthopeadic Center
773
mi
from 43215
Leesburg, FL
Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study
A Retrospective Consecutive Series Patient Preference and Clinical Outcomes Study in Bilateral Knee Osteoarthritis Patients With Both Total Knee Arthroplasty and Unicompartment Knee Arthroplasty Prostheses.
Status: Enrolling
Updated: 12/31/1969
Tri County Orthopeadic Center
773
mi
from 43215
Leesburg, FL
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis and Rheumatology Research
1663
mi
from 43215
Glendale, AZ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis and Rheumatology Research
1663
mi
from 43215
Glendale, AZ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
1654
mi
from 43215
Mesa, AZ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research, PLLC
1654
mi
from 43215
Mesa, AZ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis Research PLC
1654
mi
from 43215
Phoenix, AZ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis Research PLC
1654
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
East Bay Rheumatology Medical Group, Inc.
2093
mi
from 43215
San Leandro, CA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
East Bay Rheumatology Medical Group, Inc.
2093
mi
from 43215
San Leandro, CA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis & osteoporosis treatment center,PA
681
mi
from 43215
Orange Park, FL
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis & osteoporosis treatment center,PA
681
mi
from 43215
Orange Park, FL
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Physician's Clinic of Iowa, P.C.
471
mi
from 43215
Cedar Rapids, IA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Physician's Clinic of Iowa, P.C.
471
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
781
mi
from 43215
Wichita, KA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
781
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Klein & Associates, MD, PA
226
mi
from 43215
Cumberland, MD
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Klein & Associates, MD, PA
226
mi
from 43215
Cumberland, MD
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Klein & Associates MD, PA.
282
mi
from 43215
Hagerstown, MD
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Klein & Associates MD, PA.
282
mi
from 43215
Hagerstown, MD
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis, Rheumatic & Back Disease Associates
427
mi
from 43215
Voorhees, NJ
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis, Rheumatic & Back Disease Associates
427
mi
from 43215
Voorhees, NJ
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Robert A. Harrell, III, MD
354
mi
from 43215
Durham, NC
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Robert A. Harrell, III, MD
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Care and Diagnostic Center
911
mi
from 43215
Dallas, TX
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Care and Diagnostic Center
911
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Seattle Rheumatology Associates
2006
mi
from 43215
Seattle, WA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Seattle Rheumatology Associates
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Northwest Rheumatology
1778
mi
from 43215
Spokane, WA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Northwest Rheumatology
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Florida Medical Clinic
812
mi
from 43215
Zephyrhills, FL
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Florida Medical Clinic
812
mi
from 43215
Zephyrhills, FL
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Medical Center
607
mi
from 43215
Worcester, MA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Medical Center
607
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Pennsylvania Regional Center for Arthritis & Osteoarthritis
373
mi
from 43215
Wyomissing, PA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Pennsylvania Regional Center for Arthritis & Osteoarthritis
373
mi
from 43215
Wyomissing, PA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Pioneer Research Solutions
830
mi
from 43215
Cypress, TX
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Pioneer Research Solutions
830
mi
from 43215
Cypress, TX
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
University of California, Davis - Health Systems
2042
mi
from 43215
Sacramento, CA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
University of California, Davis - Health Systems
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Glacier View Research Institute
1640
mi
from 43215
Kalispell, MT
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Glacier View Research Institute
1640
mi
from 43215
Kalispell, MT
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Physicians at Brooklyn Heights
280
mi
from 43215
Brooklyn, NY
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Physicians at Brooklyn Heights
280
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Rheumatology
1856
mi
from 43215
Kennewick, WA
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Rheumatology
1856
mi
from 43215
Kennewick, WA
Click here to add this to my saved trials
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
5187
mi
from 43215
Plovdiv,
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
5187
mi
from 43215
Plovdiv,
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Stanford University Medical Center
2102
mi
from 43215
Palo Alto, CA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Stanford University Medical Center
2102
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Medical Center
2111
mi
from 43215
San Francisco, CA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Medical Center
2111
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
270
mi
from 43215
Chicago, IL
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
166
mi
from 43215
Indianapolis, IN
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
643
mi
from 43215
Boston, MA
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
618
mi
from 43215
Kansas City, MO
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
HackensackUniversity Medical Center
475
mi
from 43215
Hackensack, NJ
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
HackensackUniversity Medical Center
475
mi
from 43215
Hackensack, NJ
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Children's Hospital at Montefiore
485
mi
from 43215
Bronx, NY
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Children's Hospital at Montefiore
485
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
480
mi
from 43215
New York, NY
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated:  12/31/1969
Duke Children's Hospital and Health Center
354
mi
from 43215
Durham, NC
Start Time Optimization of Biologics in Polyarticular JIA
Start Time Optimization of Biologics in Polyarticular JIA
Status: Enrolling
Updated: 12/31/1969
Duke Children's Hospital and Health Center
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials